Analysis of LRRN3 , MEF2C , SLC22A , and P2RY12 Gene Expression in the Peripheral Blood of Patients in the Early Stages of Parkinson's Disease

• Published in: Biomedicines Vol. 12; no. 7; p. 1391
• Main Authors: Shulskaya, Marina V, Semenova, Ekaterina I, Rudenok, Margarita M, Partevian, Suzanna A, Lukashevich, Maria V, Karabanov, Alexei V, Fedotova, Ekaterina Yu, Illarioshkin, Sergey N, Slominsky, Petr A, Shadrina, Maria I, Alieva, Anelya Kh
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 23-06-2024
• Subjects: Biomarkers; Blood levels; Developmental stages; Disease; Gene expression; Movement disorders; Neurodegenerative diseases; Neurology; Parkinson's disease; Peripheral blood; Proteins; Regeneration; Transfer RNA; United States > US; Russia; Parkinson’s disease; gene expression; peripheral blood
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines12071391

Parkinson's disease (PD) is one of the most common human neurodegenerative diseases. Belated diagnoses of PD and late treatment are caused by its elongated prodromal phase. Thus, searching for new candidate genes participating in the development of the pathological process in the early stages of the disease in patients who have not yet received therapy is relevant. Changes in mRNA and protein levels have been described both in the peripheral blood and in the brain of patients with PD. Thus, analysis of changes in the mRNA expression in peripheral blood is of great importance in studying the early stages of PD. This work aimed to analyze the changes in
,
,
, and
gene expression in the peripheral blood of patients in the early stages of PD. We found a statistically relevant and PD-specific change in the expression of the
gene, indicating a disruption in the processes of neuronal regeneration and the functioning of synapses. The data obtained during the study indicate that this gene can be considered a potential biomarker of the early stages of PD.